Imaging Agents for Inflammatory Components of Malignancy
Imaging Agents for Inflammatory Components of Malignancy
批准号:
10226210
负责人:
MARTIN G POMPER
金额:
$25.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2024-06-30
关键词:
AddressAffinityAnaphylatoxinsAnatomyAntibodiesAutomobile DrivingBindingBreastC3AR1 geneCAR T cell therapyCellsCessation of lifeClinicClinicalCommunitiesComplementComplement ReceptorCyclic GMPCytotoxic T-LymphocytesDataData AnalysesDiseaseDoctor of MedicineDoctor of PhilosophyFailureFundingHumanImageImage-Guided SurgeryImmuneImmunityImmunohistochemistryImmunologicsImmunooncologyImmunosuppressionImmunotherapyInflammationInflammatoryInstitutesInter-tumoral heterogeneityLabelLeadLigandsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMeasuresMedicalMedical OncologyMolecular WeightMonitorNatural ImmunityNeoadjuvant TherapyNeuraxisNew AgentsNon-Invasive Cancer DetectionNon-Small-Cell Lung CarcinomaPathologicPatientsPeptidesPlayPositron-Emission TomographyProcessPropertyProteinsReagentReportingResearch PersonnelResourcesRoleSeriesServicesSiteSpecificityStructureTechniquesTherapeuticTherapeutic antibodiesTissuesToxic effectTranslatingTumor PromotersTumor-infiltrating immune cellsVaccinesValidationadaptive immunityanalogbasecancer immunotherapycannabinoid receptorcheckpoint inhibitioncheckpoint therapycomplement systemfirst-in-humanimaging agentimmune checkpointin vivointerestmacrophagemalignant breast neoplasmmolecular imagingmouse modelneoplastic cellneuroinflammationnext generationnon-invasive imagingoverexpressionpancreatic cancer patientspre-clinicalprecision medicinepredictive markerprogrammed cell death ligand 1programmed cell death protein 1radiotracerreceptorrecruitrelease factorside effectsmall moleculesuccesstargeted agenttargeted imagingtargeted treatmenttherapeutic targettreatment responsetumortumor growthtumor progressionuser-friendlyvalidation studies
中文摘要
tr&d 3总结
英文摘要
SUMMARY FOR TR&D 3
TR&D 3 of the BTRC will develop imaging agents to detect inflammation and immunity, with a focus on small
molecule PET agents to monitor immunotherapy, an increasing medical need. Inflammation has long been
recognized as a promoter of tumor growth. More recently, harnessing innate and adaptive immunity to treat
cancer through immune checkpoint inhibition and vaccines has captivated the community of cancer researchers
and clinicians alike. We will develop and disseminate agents that address two different aspects of cancer and its
relationships to inflammation and immunity, namely, checkpoint inhibition and complement. The immune
checkpoint protein programmed death-ligand 1 (PD-L1) and its receptor PD-1 are preferred targets for cancer
immunotherapy. PD-L1 is expressed by a variety of tumors, and its over-expression is induced in tumor cells to
adapt to tumor infiltrating cytotoxic T cells. PD-L1 immunohistochemistry (IHC) is the best predictive biomarker
for therapeutic monitoring of PD-L1/PD-1 targeted therapies. However, PD-L1 IHC is fraught with use of
discordant antibodies, intra- and inter-tumoral heterogeneity of expression as well as limited bio-specimen
availability such that we believe non-invasive imaging can help. Furthermore, despite the promise of immune
checkpoint therapy, the majority of patients do not respond for reasons unclear. The complement system is
central to recruiting inflammatory cells and promoting release of factors that can promote tumor growth and
progression, confounding immunotherapy. We will synthesize, validate and disseminate agents targeting PD-L1
(Aim 1) and complement receptors C3aR and C5aR (Aim 2), which are bound by their cognate tumor-promoting
anaphylatoxins. In Aim 3 we will validate – with correlation to post-imaging surgical tissue – a current BTRC lead
PD-L1 imaging agent in patients undergoing immunotherapy for pancreas cancer through support from the
Bloomberg-Kimmel Institute for Immunotherapy. Once validated in this ultimate fashion we will be confident to
disseminate that agent for human studies elsewhere. TR&D 3 will also serve as the Clinical Validation Core, a
hub that will disseminate not only valuable new human agents as noted above, but will also provide precursor
and standard for other agents, allow cross-referencing of BTRC INDs and provide analysis to meet the evolving
needs of the driving Collaborative Projects and service recipients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
-
批准号:10698133
-
项目类别:
-
资助金额:$28.94万
-
财政年份:2022
-
负责人:MARTIN G POMPER
-
依托单位:
Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
-
批准号:10518916
-
项目类别:
-
资助金额:$35.03万
-
财政年份:2022
-
负责人:MARTIN G POMPER
-
依托单位:
Resource for Molecular Imaging Agents in Precision Medicine
-
批准号:10226206
-
项目类别:
-
资助金额:$117.95万
-
财政年份:2017
-
负责人:MARTIN G POMPER
-
依托单位:
Administration - Resource for Molecular Imaging Agents in Precision Medicine
-
批准号:10226207
-
项目类别:
-
资助金额:$7.79万
-
财政年份:2017
-
负责人:MARTIN G POMPER
-
依托单位:
Training/Dissemination - Resource for Molecular Imaging Agents in Precision Medicine
-
批准号:10226214
-
项目类别:
-
资助金额:$9.33万
-
财政年份:2017
-
负责人:MARTIN G POMPER
-
依托单位:
Small Molecule PSMA-Targeted Alpha Therapy
-
批准号:10594010
-
项目类别:
-
资助金额:$42.39万
-
财政年份:2014
-
负责人:MARTIN G POMPER
-
依托单位:
Small Molecule PSMA-Targeted Alpha Therapy
-
批准号:10411890
-
项目类别:
-
资助金额:$36.22万
-
财政年份:2014
-
负责人:MARTIN G POMPER
-
依托单位:
Small Molecule PSMA-Targeted Alpha Therapy
-
批准号:9886363
-
项目类别:
-
资助金额:$31.93万
-
财政年份:2014
-
负责人:MARTIN G POMPER
-
依托单位:
Small Molecule PSMA-Targeted Alpha Therapy
-
批准号:8671057
-
项目类别:
-
资助金额:$46.5万
-
财政年份:2014
-
负责人:MARTIN G POMPER
-
依托单位:
Small Molecule PSMA-Targeted Alpha Therapy
-
批准号:10092113
-
项目类别:
-
资助金额:$38.96万
-
财政年份:2014
-
负责人:MARTIN G POMPER
-
依托单位:
Validation
-
批准号:7984058
-
项目类别:
-
资助金额:$14.15万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
TK-based Infection Imaging
-
批准号:8459010
-
项目类别:
-
资助金额:$43.24万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
Center of Cancer Nanotechnology Excellence at Johns Hopkins
-
批准号:8133492
-
项目类别:
-
资助金额:$259.42万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
Center of Cancer Nanotechnology Excellence at Johns Hopkins
-
批准号:8734334
-
项目类别:
-
资助金额:$232.64万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
Center of Cancer Nanotechnology Excellence at Johns Hopkins
-
批准号:7977093
-
项目类别:
-
资助金额:$274.05万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
Center of Cancer Nanotechnology Excellence at Johns Hopkins
-
批准号:8545547
-
项目类别:
-
资助金额:$175.81万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
TK-based Infection Imaging
-
批准号:8263491
-
项目类别:
-
资助金额:$5.74万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
Developmental Activities
-
批准号:7984070
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
TK-based Infection Imaging
-
批准号:7887219
-
项目类别:
-
资助金额:$60.12万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
TK-based Infection Imaging
-
批准号:8072567
-
项目类别:
-
资助金额:$48.18万
-
财政年份:2010
-
负责人:MARTIN G POMPER
-
依托单位:
海外基金